Oral PDE4 inhibitors in the management of stable COPD
Almost 1.45 million Australians have some form of chronic obstructive pulmonary disease (COPD). This equates to one in seven Australians over 40 suffering from...
Pharmacists scramble to protect remote communities from COVID-19
Clusters of infection in regional and remote areas continue to grow, with overworked pharmacists adapting their services to minimise the spread.
Your most pressing questions answered
This month Amanda Fairjones, Professional Support Advisor, and Peter Guthrey, Senior Pharmacist answer your questions about COVID-19 vaccine requirements and the new nicotine vaping guidelines.
E-prescriptions, triptans and COVID-19 vaccines: your questions answered
In this monthly series, Australian Pharmacist speaks to the experts to answer some of your most frequently asked questions.
Expect an increase in demand for long-acting injectable buprenorphine
Changes to the Opioid Dependence Treatment program could make long-acting injectable buprenorphine the best option for many people.
Changes to PBS antibiotic prescribing
In a move aimed at reducing antibiotic resistance, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that four of the most widely prescribed antibiotics...
